This clinical trial studies how well positron emission tomography (PET)/computed tomography (CT) works compared to PET/magnetic resonance imaging (MRI) in evaluating patients with cancer. PET/CT and PET/MRI may determine which scanner is best for the patient’s type of cancer and other types of cancers.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03125629.
PRIMARY OBJECTIVES:
I. To evaluate if 18F fludeoxyglucose (FDG) PET/CT and 18F FDG PET/MRI scanners provide equivalent results for evaluation of cancer patients.
OUTLINE:
Patients receive 18F FDG intravenously (IV). Within 45-60 minutes, patients then undergo PET/CT imaging followed by PET/MRI over 90 minutes total at week 1.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationStanford Cancer Institute Palo Alto
Principal InvestigatorAndrei Iagaru
